• 1
    Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005; 23: 81468151
  • 2
    Abdollah F, Sun M, Schmitges J et al. Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 2012; 84: 95103
  • 3
    Abdollah F, Sun M, Schmitges J et al. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol 2011; 60: 920930
  • 4
    Abdollah F, Sun M, Thuret R et al. A competing-risks analysis of survival after alternative treatment modalities for prostate cancer patients: 1988–2006. Eur Urol 2011; 59: 8895
  • 5
    Bastian PJ, Carter BH, Bjartell A et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol 2009; 55: 13211330
  • 6
    Tosoian JJ, Trock BJ, Landis P et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 21852190
  • 7
    van den Bergh RC, Roemeling S, Roobol MJ et al. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly. Eur Urol 2009; 55: 18
  • 8
    Whitson JM, Porten SP, Hilton JF et al. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol 2011; 185: 16561660
  • 9
    Adamy A, Yee DS, Matsushita K et al. Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011; 185: 477482
  • 10
    Scattoni V, Raber M, Abdollah F et al. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010; 57: 18
  • 11
    Scattoni V, Raber M, Capitanio U et al. The optimal rebiopsy prostatic scheme depends on patient clinical characteristics: results of a recursive partitioning analysis based on a 24-core systematic scheme. Eur Urol 2011; 60: 834841
  • 12
    Montorsi F, Salonia A, Suardi N et al. Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. Eur Urol 2005; 48: 938945
  • 13
    Walsh PC. Preservation of sexual function in the surgical treatment of prostatic cancer – an anatomic surgical approach. Important Adv Oncol 1988; 161170
  • 14
    Briganti A, Larcher A, Abdollah F et al. Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 2012; 61: 480487
  • 15
    McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897906
  • 16
    Capitanio U, Suardi N, Briganti A et al. Influence of obesity on tumour volume in patients with prostate cancer. BJU Int 2012; 109: 678684
  • 17
    Wolters T, Roobol MJ, van Leeuwen PJ et al. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185: 121125
  • 18
    Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29: 36693676
  • 19
    Ploussard G, de la Taille A, Terry S et al. Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urol Oncol 2012; doi: 10.1016/j.urolonc.2011.12.018 [Epub ahead of print]
  • 20
    Suardi N, Briganti A, Gallina A et al. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. BJU Int 2010; 105: 15481552
  • 21
    Suardi N, Capitanio U, Chun FK et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113: 20682072
  • 22
    Iremashvili V, Pelaez L, Manoharan M, Jorda M, Rosenberg DL, Soloway MS. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols. Eur Urol 2012; 62: 462468
  • 23
    Suardi N, Gallina A, Capitanio U et al. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer 2012; 118: 973980
  • 24
    Albertsen PC, Hanley JA, Barrows GH et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 12481253